Arena Pharma recorded third-quarter revenues of $8.2 million, below the Zacks Consensus Estimate of $10 million.

The average small cap score is 51.24 this week, below the four week moving average score of 52.96. The average small cap stock is trading -26.83% below its 52 week high, -2.81% below its 200 dma, and has 8.37 days to cover held short.

The FDA has approved Orexigen Therapeutics' (OREX) weight-management drug, Contrave. But is it a buy when similar products such as ARNA's Belviq, GSSK's Orlistat and VVUS's Qsymia – been unable to create traction in sales?

The average small cap score is 53.19 this week, below the four week moving average score of 53.26. The average small cap stock is trading -25.22% below its 52 week high, -1.01% below its 200 dma, and has 8.37 days to cover held short.

The average small cap score is 52.43 this week, above the four week moving average score of 50.99. The average small cap is trading -25.41% below its 52 week high, -2.14% below its 200 dma, and has 8.37 days to cover held short.

360 Biotech's contrarian thesis on the weight loss drugs developer published in 2013 was unwelcoming but turned out valid. Stock promoters who were overly exuberant on Arena, Orexigen, and/or VIVUS mislead investors.